Opportunity Information: Apply for PAR 23 165
The National Institutes of Health (NIH) is soliciting R01 research grant applications under FOA PAR 23-165, titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)." The core purpose of this opportunity is to support the preclinical creation and validation of new radioligands that can be used as brain imaging biomarkers with positron emission tomography (PET) or single photon emission computed tomography (SPECT). In practical terms, NIH is looking for projects that design and optimize novel PET/SPECT ligands and then demonstrate, in rigorous preclinical settings, that these ligands can reliably measure relevant biological targets in the central nervous system (CNS). The broader motivation is to strengthen biomarker tools that can accelerate drug discovery and deepen understanding of disease mechanisms across CNS disorders.
This FOA emphasizes work that is fundamentally preclinical, with strong expectations for testing in rodent and nonhuman primate brain. The focus is on the step-by-step development pipeline that takes a candidate radiotracer from concept through evidence of performance, including appropriate model development when needed. The announcement also allows for incorporation of pilot or feasibility-style evaluation as part of the preclinical effort, meaning applicants can propose carefully scoped studies that show whether a ligand is likely to work as an imaging tool, how it behaves in the brain, and whether it has the properties needed to become a practical biomarker. At the same time, the FOA draws a clear line around clinical research: this is an "R01 Clinical Trial Not Allowed" announcement, and applicants who want to conduct clinical assessments of novel radioligands are directed to submit to a different FOA (referenced as PAR XX-XXX in the provided text).
The scientific scope centers on radioligand development for CNS applications, which typically includes activities such as identifying or engineering compounds with high affinity and selectivity for a biological target, radiolabeling chemistry suitable for PET or SPECT isotopes, and demonstrating brain penetration and signal quality. Competitive projects would be expected to show that a ligand provides a measurable and interpretable imaging signal, supports quantification strategies, and has acceptable properties related to specificity, kinetics, and overall feasibility for neuroimaging. Because the FOA explicitly frames these ligands as biomarkers, it is oriented toward tools that can be used to answer concrete questions in drug discovery (for example, target engagement, receptor occupancy, or pharmacodynamics) and in pathophysiological studies (for example, mapping target changes across disease models or probing mechanisms relevant to CNS disorders).
In terms of eligibility, the program is broadly open. Eligible applicants include a wide range of U.S. governmental entities (state, county, city or township, special districts), public and state-controlled institutions of higher education, private institutions of higher education, independent school districts, and public housing/Indian housing authorities. It also includes federally recognized Native American tribal governments, as well as Native American tribal organizations and tribal governments that are not federally recognized, and a variety of nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education in those nonprofit categories). For-profit entities (other than small businesses) and small businesses are also eligible, and NIH explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This wide eligibility is consistent with the technical and interdisciplinary nature of radioligand development, which often draws on chemistry, pharmacology, imaging physics, neurobiology, and translational biomarker expertise.
Administratively, this is a discretionary grant opportunity using the NIH research project grant mechanism (R01). The funding activity category is health, and the opportunity is associated with CFDA numbers 93.242 and 93.866. The FOA was created on 2023-04-07, and the listed original closing date is 2026-05-07. The excerpt provided does not specify an award ceiling or expected number of awards, so applicants would need to consult the full FOA and related NIH budget guidance for details on typical award sizes, allowable costs, project duration expectations, and any institute- or center-specific priorities.
Overall, this opportunity is aimed at teams that can deliver strong, preclinical evidence that a new PET or SPECT radioligand can function as a credible CNS imaging biomarker. Projects should be framed around generating usable imaging tools that can meaningfully support drug discovery decisions and mechanistic studies of CNS disorders, while avoiding proposals that cross into clinical trial territory under this particular "clinical trial not allowed" R01 announcement.Apply for PAR 23 165
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.866.
- This funding opportunity was created on 2023-04-07.
- Applicants must submit their applications by 2026-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is an NIH R01 research grant solicitation under FOA PAR 23-165 titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)."
What is the main purpose of PAR 23-165?
The core purpose is to support the preclinical creation and validation of new radioligands that can be used as brain imaging biomarkers with positron emission tomography (PET) or single photon emission computed tomography (SPECT). The emphasis is on designing and optimizing novel ligands and then demonstrating in rigorous preclinical settings that they can reliably measure relevant biological targets in the central nervous system (CNS).
What kinds of projects is NIH looking for under this FOA?
NIH is looking for projects that follow a step-by-step preclinical development pipeline for PET/SPECT radioligands, taking candidates from concept through evidence of performance as CNS imaging biomarkers. Competitive projects are expected to include development and optimization of ligands and strong preclinical evidence showing interpretable imaging signal and feasibility as a biomarker tool.
Is the focus preclinical or clinical?
The focus is fundamentally preclinical. The FOA places strong expectations on testing in rodent and nonhuman primate brain and draws a clear boundary around clinical research.
Are clinical trials allowed under this R01?
No. This is an "R01 Clinical Trial Not Allowed" funding opportunity. Proposals that include clinical assessments of novel radioligands are expected to be submitted to a different FOA referenced in the provided text as PAR XX-XXX.
Does the FOA support pilot or feasibility-style work?
Yes. The FOA allows incorporation of pilot or feasibility-style evaluation as part of the preclinical effort, such as carefully scoped studies that assess whether a ligand is likely to work as an imaging tool and whether it has properties needed to become a practical biomarker.
What imaging modalities are supported?
The FOA is specifically focused on radioligands used with PET or SPECT for brain imaging biomarker applications in CNS disorders.
What scientific activities are typically within scope?
Activities described as typical for the scope include identifying or engineering compounds with high affinity and selectivity for a biological target, radiolabeling chemistry suitable for PET or SPECT isotopes, and demonstrating brain penetration and signal quality. Projects are also expected to support quantification strategies and evaluate properties such as specificity, kinetics, and overall feasibility for neuroimaging.
What does NIH mean by using PET/SPECT ligands as biomarkers in this FOA?
In this FOA, radioligands are framed as biomarkers that can be used as practical tools to answer concrete questions in drug discovery and pathophysiological studies of CNS disorders, such as measuring target engagement, receptor occupancy, pharmacodynamics, mapping target changes across disease models, or probing disease-relevant mechanisms.
What kinds of biological or disease areas does this FOA target?
The scientific focus is CNS disorders and CNS-relevant biological targets that can be measured using PET or SPECT radioligands as brain imaging biomarkers.
What species or model systems are expected for evaluation?
The FOA emphasizes rigorous preclinical testing with strong expectations for studies in rodent and nonhuman primate brain.
Is model development allowed or expected?
Yes. The FOA notes that appropriate model development may be included when needed as part of the overall development pipeline for a candidate radiotracer.
What is the grant mechanism used for this opportunity?
The opportunity uses the NIH Research Project Grant mechanism (R01).
What is the funding activity category?
The funding activity category is health.
What are the associated CFDA numbers?
The opportunity is associated with CFDA numbers 93.242 and 93.866.
Who is eligible to apply?
Eligibility is broad. The FOA allows applications from a wide range of entities, including U.S. governmental entities (state, county, city or township, special districts), public and state-controlled institutions of higher education, private institutions of higher education, independent school districts, public housing/Indian housing authorities, federally recognized Native American tribal governments, and tribal organizations and tribal governments that are not federally recognized. It also includes nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education in those nonprofit categories), for-profit entities (other than small businesses), small businesses, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations).
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility list includes non-U.S. entities (foreign organizations).
Are for-profit organizations eligible?
Yes. For-profit entities (other than small businesses) and small businesses are both listed as eligible applicants.
Are minority-serving institutions and community-based organizations included?
Yes. The eligibility description explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
When was this FOA created?
The FOA was created on 2023-04-07.
What is the closing date listed in the provided information?
The listed original closing date is 2026-05-07.
Does the provided excerpt specify an award ceiling or expected number of awards?
No. The excerpt provided does not specify an award ceiling or the expected number of awards.
Where should applicants look for budget size, allowable costs, and project duration expectations?
Based on the provided information, applicants would need to consult the full FOA and related NIH budget guidance for details on typical award sizes, allowable costs, project duration expectations, and any institute- or center-specific priorities.
What makes an application competitive based on this description?
Based on the information provided, competitive projects would be expected to (1) design and optimize novel PET/SPECT ligands, (2) produce rigorous preclinical evidence (with emphasis on rodent and nonhuman primate brain) that the ligand provides a measurable and interpretable imaging signal, (3) support quantification strategies, and (4) demonstrate acceptable properties related to specificity, kinetics, brain penetration, signal quality, and overall feasibility as a CNS imaging biomarker.
What should applicants avoid proposing under this FOA?
Applicants should avoid proposing clinical research or clinical assessments of novel radioligands under this particular FOA because it is explicitly "clinical trial not allowed." The provided information indicates that clinical assessments should be directed to a different FOA (referenced as PAR XX-XXX).
Browse more opportunities from the same category: Health
Next opportunity: Ending the HIV Epidemic: Focus on Justice Populations with SUD (R61/R33 Clinical Trial Required)
Previous opportunity: Pathways into the Earth, Ocean, Polar and Atmospheric & Geospace Sciences
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 165
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 165) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Apply for PAR 23 164 Funding Number: PAR 23 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for PAR 23 154 Funding Number: PAR 23 154 Agency: National Institutes of Health Category: Health Funding Amount: $360,000 |
| Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) Apply for PAR 23 163 Funding Number: PAR 23 163 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) Apply for PAR 23 098 Funding Number: PAR 23 098 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH): Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 23 106 Funding Number: RFA MH 23 106 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional) Apply for RFA MH 23 105 Funding Number: RFA MH 23 105 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 023 Funding Number: RFA AI 23 023 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed Apply for PAR 23 268 Funding Number: PAR 23 268 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed) Apply for PAR 23 267 Funding Number: PAR 23 267 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 23 168 Funding Number: PAR 23 168 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Draft Notice of Funding Opportunity - Children, Adolescents, and Families in the HIV Epidemic in Free State Province Apply for 72067423RFI00003 Funding Number: 72067423RFI00003 Agency: South Africa USAID-Pretoria Category: Health Funding Amount: Case Dependent |
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed) Apply for PAR 23 149 Funding Number: PAR 23 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required) Apply for PAR 23 150 Funding Number: PAR 23 150 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) Apply for PAR 23 169 Funding Number: PAR 23 169 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 23 026 Funding Number: RFA AI 23 026 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional) Apply for PAR 23 179 Funding Number: PAR 23 179 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional) Apply for PAR 23 145 Funding Number: PAR 23 145 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Nursing Home EXplanatory Clinical Trials Network (NEXT) (U24 Clinical Trial Required) Apply for RFA AG 24 016 Funding Number: RFA AG 24 016 Agency: National Institutes of Health Category: Health Funding Amount: $2,300,000 |
| Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional) Apply for RFA EB 23 005 Funding Number: RFA EB 23 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed) Apply for PAR 23 175 Funding Number: PAR 23 175 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 165", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.